Assessment of CSF levels of tau protein in patients with Alzheimer's disease and mild dementia

Neurology ◽  
1997 ◽  
Vol 49 (6) ◽  
pp. 1753-1753 ◽  
Author(s):  
D. R. Gifford
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Tau Protein ◽  
Mild Dementia ◽  
Csf Levels

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

Neurology ◽  
1997 ◽  
Vol 48 (3) ◽  
pp. 632-635 ◽  
Author(s):  
D. Galasko ◽  
C. Clark ◽  
L. Chang ◽  
B. Miller ◽  
R. C. Green ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Tau Protein ◽  
Csf Levels

Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer's Disease

2020 ◽  
Vol 20 (12) ◽  
pp. 1059-1073 ◽  
Author(s):  
Ahmad Abu Turab Naqvi ◽  
Gulam Mustafa Hasan ◽  
Md. Imtaiyaz Hassan
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Tau Protein ◽  
Glycogen Synthase ◽  
Paired Helical Filaments ◽  
Tau Hyperphosphorylation ◽  
Microtubule Stabilization ◽  
Extracellular Signal

Microtubule-associated protein tau is involved in the tubulin binding leading to microtubule stabilization in neuronal cells which is essential for stabilization of neuron cytoskeleton. The regulation of tau activity is accommodated by several kinases which phosphorylate tau protein on specific sites. In pathological conditions, abnormal activity of tau kinases such as glycogen synthase kinase-3 β (GSK3β), cyclin-dependent kinase 5 (CDK5), c-Jun N-terminal kinases (JNKs), extracellular signal-regulated kinase 1 and 2 (ERK1/2) and microtubule affinity regulating kinase (MARK) lead to tau hyperphosphorylation. Hyperphosphorylation of tau protein leads to aggregation of tau into paired helical filaments like structures which are major constituents of neurofibrillary tangles, a hallmark of Alzheimer’s disease. In this review, we discuss various tau protein kinases and their association with tau hyperphosphorylation. We also discuss various strategies and the advancements made in the area of Alzheimer's disease drug development by designing effective and specific inhibitors for such kinases using traditional in vitro/in vivo methods and state of the art in silico techniques.

scholarly journals A current view on Tau protein phosphorylation in Alzheimer's disease

2021 ◽  
Vol 69 ◽  
pp. 131-138
Author(s):  
Susanne Wegmann ◽  
Jacek Biernat ◽  
Eckhard Mandelkow
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Protein Phosphorylation ◽  
Tau Protein ◽  
Current View ◽  
A Current

scholarly journals Platelet APP‐ratio correlates with CSF levels of Aβ1‐42 in Alzheimer’s disease patients

2020 ◽  
Vol 16 (S5) ◽  
Author(s):  
Tamires Alves Sarno ◽  
Leda Leme Talib ◽  
Helena Passarelli Giroud Joaquim ◽  
Marcia Radanovic ◽  
Jessyka Maria de França Bram ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Csf Levels ◽  
App Ratio

Comparing the neuropsychological profiles of mild dementia with Lewy bodies and mild Alzheimer’s disease

2018 ◽  
Vol 18 (1) ◽  
pp. 64-71
Author(s):  
Yan Xu ◽  
Keliang Chen ◽  
Qianhua Zhao ◽  
Qihao Guo
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Mild Dementia
Sign in / Sign up

Export Citation Format

Share Document